ATE Insider Trading

Insider Ownership Percentage: 7.94%
Insider Buying (Last 12 Months): C$19,600.00
Insider Selling (Last 12 Months): C$0.00

Antibe Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Antibe Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Antibe Therapeutics Share Price & Price History

Current Price: C$0.00
Price Change: +0.30 (1.20%)
As of 04/8/2024 10:01 PM ET

This chart shows the closing price history over time for ATE up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Antibe Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/7/2024Daniel Marcel LegaultDirectorBuy20,000C$0.50C$10,000.00
3/6/2024Joseph StaufferSenior OfficerBuy24,000C$0.40C$9,600.00
11/15/2022Daniel Marcel LegaultDirectorBuy40,000C$0.49C$19,400.00983,296
11/15/2022Scott Wilson CurtisSenior OfficerBuy20,000C$0.50C$10,000.00100,000
7/15/2022John Lawrence WallaceDirectorSell5,000C$0.62C$3,100.001,772,976
7/11/2022Daniel Marcel LegaultDirectorBuy7,500C$0.60C$4,500.00888,796
7/8/2022Scott Wilson CurtisSenior OfficerBuy20,000C$0.62C$12,400.0080,000
7/7/2022John Lawrence WallaceDirectorSell21,500C$0.62C$13,330.001,899,576
11/10/2021Walter Minnes MacneeDirectorBuy50,000C$0.90C$45,000.00497,027
11/3/2021Walter Minnes MacneeDirectorBuy25,000C$0.98C$24,385.00447,027
11/1/2021Daniel Marcel LegaultDirectorBuy2,500C$0.92C$2,300.00778,796
11/1/2021Scott Wilson CurtisSenior OfficerBuy13,000C$0.88C$11,440.0060,000
8/4/2021Daniel Marcel LegaultDirectorBuy12,500C$1.02C$12,750.00776,296
7/14/2021Scott Wilson CurtisSenior OfficerBuy2,600C$3.42C$8,892.0037,000
7/13/2021Daniel Marcel LegaultDirectorBuy4,000C$3.57C$14,280.00763,796
6/30/2021Daniel Marcel LegaultDirectorBuy4,000C$3.70C$14,800.00759,796
See Full Table

SEC Filings (Institutional Ownership Changes) for Antibe Therapeutics (TSE:ATE)

Antibe Therapeutics logo
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.
Read More on Antibe Therapeutics

Today's Range

Now: N/A

50 Day Range

MA: C$0.30
Low: C$0.17
High: C$0.45

52 Week Range

Now: N/A

Volume

167,042 shs

Average Volume

135,475 shs

Market Capitalization

C$15.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.19

Who are the company insiders with the largest holdings of Antibe Therapeutics?

Antibe Therapeutics' top insider investors include:
  1. John Lawrence Wallace (Director)
  2. Daniel Marcel Legault (Director)
  3. Scott Wilson Curtis (Senior Officer)
  4. Joseph Stauffer (Senior Officer)
Learn More about top insider investors at Antibe Therapeutics.